NDASUBCUTANEOUSSOLUTION
Approved
Nov 2025
Lifecycle
Launch
Competitive Pressure
0/100
Clinical Trials
9
Data completeness
4/8 — Partial
REDEMPLO (plozasiran) by Arrowhead Pharmaceuticals. Approved for severe hypertriglyceridemia, familial chylomicronemia syndrome. First approved in 2025.
Drug data last refreshed 22h ago
Mechanism of Action
Pharmacologic Class:
APOC-III-directed RNA Interaction
Worked on REDEMPLO at Arrowhead Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.